Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
We recently reported that mice deficient in the programmed cell death-1 (PD-1) immunoinhibitory coreceptor develop autoimmune dilated cardiomyopathy (DCM), with production of high-titer autoantibodies against a heart-specific, 30-kDa protein. In this study, we purified the 30-kDa protein from heart extract and identified it as cardiac troponin I (cTnI), encoded by a gene in which mutations can cause familial hypertrophic cardiomyopathy (HCM). Administration of monoclonal antibodies to cTnI induced dilatation and dysfunction of hearts in wild-type mice. Monoclonal antibodies to cTnI stained the surface of cardiomyocytes and augmented the voltage-dependent L-type Ca2+ current of normal cardiomyocytes. These findings suggest that antibodies to cTnI induce heart dysfunction and dilatation by chronic stimulation of Ca2+ influx in cardiomyocytes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the cardiotoxicity of anti-cTnI autoantibodies has been reported in studies using BALB/c mice lacking PD-1 expression”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“PD-1-deficient BALB/c mice spontaneously developed autoimmune DCM mediated by anti-cTnI antibodies, and the pathology was transferable when wild-type mice were treated with these autoantibodies”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“suggesting a potential mechanism of ICI myocarditis.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“the cardiotoxicity of anti-cTnI antibodies has been reported in PD-1 -/- BALB/c mice”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
In the citing paper
“However, these autoantibodies are generally not disease-specific and may not consistently induce the disease phenotype in murine models, indicating their limitations as diagnostic and therapeutic targets. 57,92,97,191”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [97]
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citationThe Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046
Calcium tolerant ventricular myocytes prepared by preincubation in a ?KB medium?
Isenberg, G., & Klockner, U. (1982) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/bf00584963 · Cited by 898
Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy
Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P., McDonough, B., Smoot, L., Mullen, M. P., Woolf, P. K., Wigle, E. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432304 · Cited by 720
Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
Kimura, A., Harada, H., Park, J.-E., Nishi, H., Satoh, M., Takahashi, M., Hiroi, S., Sasaoka, T., Ohbuchi, N., Nakamura, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0897-379 · Cited by 577
Cardiac myosin induces myocarditis in genetically predisposed mice.
Neu, N., Rose, N. R., Beisel, K. W., Herskowitz, A., Gurri-Glass, G., & Craig, S. W. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.11.3630 · Cited by 526
Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12
Shou, W., Aghdasi, B., Armstrong, D. L., Guo, Q., Bao, S., Charng, M.-J., Mathews, L. M., Schneider, M. D., Hamilton, S. L., & Matzuk, M. M. (1998) · Nature · doi:10.1038/35146 · Cited by 431
Cited by
Items 101–200 of 688
Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez-Almazor, M. E., Kim, S. T., Abdel‐Wahab, N., & Diab, A. K. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40043 · Cited by 131
Leuschner, F., Li, J., Goser, S., Reinhardt, L., Ottl, R., Bride, P., Zehelein, J., Pfitzer, G., Remppis, A., Giannitsis, E., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn268 · Cited by 120
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 132
Ferreiros‐Vidal, I., Gomez‐Reino, J. J., Barros, F., Carracedo, A., Carreira, P., Gonzalez‐Escribano, F., Liz, M., Martin, J., Ordi, J., Vicario, J. L., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20436 · Cited by 121
Dwaich, K. H., Al-Amran, F. G., AL-Sheibani, B. I. M., & Al-Aubaidy, H. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.108 · Cited by 119
JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies
Kitaoka, H., Tsutsui, H., Kubo, T., Ide, T., Chikamori, T., Fukuda, K., Fujino, N., Higo, T., Isobe, M., Kamiya, C., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0910 · Cited by 134
Oya, Y., Watanabe, N., Owada, T., Oki, M., Hirose, K., Suto, A., Kagami, S., Nakajima, H., Kishimoto, T., Iwamoto, I., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23674 · Cited by 127
PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination
Finnefrock, A. C., Tang, A., Li, F., Freed, D. C., Feng, M., Cox, K. S., Sykes, K. J., Guare, J. P., Miller, M. D., Olsen, D. B., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.980 · Cited by 125
Kaya, Z., Göser, S., Buss, S. J., Leuschner, F., Öttl, R., Li, J., Völkers, M., Zittrich, S., Pfitzer, G., Rose, N. R., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.788711 · Cited by 123
BABA, A. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.05.012 · Cited by 113
“Time after injection (min) Time after injection (min) (4) ( 1 )”
PD-1/PD-L pathway and autoimmunity
Okazaki, T., & Wang, J. (2005) · Autoimmunity · doi:10.1080/08916930500124072 · Cited by 135
Self-citationCombinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management
Caforio, A. L. P., Marcolongo, R., Jahns, R., Fu, M. L. X., Felix, S. B., & Iliceto, S. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9364-5 · Cited by 118
Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study
Staudt, A., Hummel, A., Ruppert, J., Dörr, M., Trimpert, C., Birkenmeier, K., Krieg, T., Staudt, Y., & Felix, S. B. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.06.027 · Cited by 118
Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
Michel, L., Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.15 · Cited by 118
Autoimmune myocarditis: cellular mediators of cardiac dysfunction
Afanasyeva, M., Georgakopoulos, D., & Rose, N. R. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2004.08.009 · Cited by 115
PD-1 regulates extrathymic regulatory T-cell differentiation
Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344423 · Cited by 107
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 108
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, I., Melero, I., Ponz‐Sarvisé, M., & Álvarez, E. C. (2019) · Drug Safety · doi:10.1007/s40264-018-0774-8 · Cited by 112
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Fessas, P., Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., Alexander, J. L., & Pinato, D. J. (2020) · Immunology · doi:10.1111/imm.13141 · Cited by 105
Autoimmune Mechanisms Underlying Dilated Cardiomyopathy
Yoshikawa, T., Baba, A., & Nagatomo, Y. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1151 · Cited by 104
Clinical presentation and diagnosis of myocarditis
Caforio, A. L. P., Marcolongo, R., Basso, C., & Iliceto, S. (2015) · Heart · doi:10.1136/heartjnl-2014-306363 · Cited by 107
Ali, O. H., Bomze, D., Ring, S. S., Berner, F., Fässler, M., Diem, S., Abdou, M.-T., Hammers, C. M., Emtenani, S., Braun, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.045 · Cited by 106
Kaya, Z., Katus, H. A., & Rose, N. R. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.04.008 · Cited by 111
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Dolladille, C., Éderhy, S., Allouche, S., Dupas, Q., Gervais, R., Madelaine, J., Sassier, M., Plane, A., Comoz, F., Cohen, A. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000261 · Cited by 107
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 120
The regulation of lymphocyte activation by inhibitory receptors
Leibson, P. J. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.006 · Cited by 110
Muenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980235 · Cited by 97
High incidence of macrotroponin I with a high-sensitivity troponin I assay
Warner, J., & Marshall, G. A. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1276 · Cited by 101
Adaptive immune cells in calcific aortic valve disease
Raddatz, M. A., Madhur, M. S., & Merryman, W. D. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2019 · Cited by 126
Identifying and managing the adverse effects of immune checkpoint blockade
Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 97
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 99
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 101
Koga, N., Suzuki, J., Kosuge, H., Haraguchi, G., Onai, Y., Futamatsu, H., Maejima, Y., Gotoh, R., Saiki, H., Tsushima, F., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000145015.23656.e4 · Cited by 100
Cardiotoxicity of Immune Checkpoint Inhibitors
Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 91
Bockstahler, M., Fischer, A., Goetzke, C. C., Neumaier, H. L., Sauter, M., Kespohl, M., Müller, A., Meckes, C., Salbach, C., Schenk, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043171 · Cited by 95
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 98
Sun, S.-J., Jiao, X., Chen, Z., Cao, Q., Zhu, J., Shen, Q., Liu, Y. F., Zhang, Z., Xu, F., Shi, Y. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50996-5 · Cited by 107
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 93
Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 91
Function and regulation of the complement system in cardiovascular diseases
Oksjoki, R. K., Kovanen, P. T., Meri, S., & Pentikäinen, M. O. (2007) · Frontiers in bioscience · doi:10.2741/2419 · Cited by 88
Basics of PD-1 in self-tolerance, infection, and cancer immunity
Chikuma, S. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0958-0 · Cited by 98
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Atallah‐Yunes, S. A., Kadado, A. J., Kaufman, G. P., & Hernández-Montfort, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02927-x · Cited by 91
Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87
Giannoni, A., Giovannini, S., & Clerico, A. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.320 · Cited by 86
Tsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 87
Matsumori, A. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.10 · Cited by 95
Self-citationPD-1 as an Immune Modulatory Receptor
Yao, S., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000060 · Cited by 91
Foxp3+ Treg cells in humoral immunity
Wing, J. B., & Sakaguchi, S. (2013) · International Immunology · doi:10.1093/intimm/dxt060 · Cited by 96
The heart of the matter: Protection of the myocardium from T cells
Lichtman, A. H. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.05.004 · Cited by 96
Exploring immune checkpoints as potential therapeutic targets in atherosclerosis
Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx248 · Cited by 82
Gibson, R., Delaune, J., Szady, A., & Markham, M. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216228 · Cited by 80
Agrawal, N., Khunger, A., Vachhani, P. J., Colvin, T. A., Hattoum, A., Spangenthal, E. J., Curtis, A. B., Dy, G. K., Ernstoff, M. S., & Puzanov, I. J. (2019) · Case Reports in Oncology · doi:10.1159/000498985 · Cited by 85
Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis
Li, S., Liao, W., Chen, M., Shan, S., Song, Y., Zhang, S., Song, H., & Yuan, Z. (2013) · Inflammation · doi:10.1007/s10753-013-9718-8 · Cited by 87
Clinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 86
Autoimmune myocarditis: Past, present and future
Leuschner, F., Katus, H. A., & Kaya, Z. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.07.009 · Cited by 87
Tajmir-Riahi, A., Bergmann, T., Schmid, M., Agaimy, A., Schuler, G., & Heinzerling, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000190 · Cited by 81
Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., Salem, J.-E., Wu, S. M., Moslehi, J. J., & Zhu, H. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 76
Malaspina, T. S. D. S., Gasparoto, T. H., Nogueira, M. R. S., de Melo, E. J. F., Ikoma, M. R. V., Damante, J. H., Cavassani, K. A., Garlet, G. P., Silva, J. S., & Campanelli, A. P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1007-5 · Cited by 86
Staudt, A., Dörr, M., Staudt, Y., Böhm, M., Probst, M., Empen, K., Plötz, S., Maschke, H. E., Hummel, A., Baumann, G., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.002 · Cited by 81
Horn, S., Lueking, A., Murphy, D. B., Staudt, A., Gutjahr, C., Schulte, K., König, A. A., Landsberger, M., Lehrach, H., Felix, S. B., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200401293 · Cited by 81
Myocardial Infarction Triggers Chronic Cardiac Autoimmunity in Type 1 Diabetes
Gottumukkala, R. V. S. R. K., Lv, H., Cornivelli, L., Wagers, A. J., Kwong, R. Y., Bronson, R., Stewart, G. C., Schulze, P. C., Chutkow, W., Wolpert, H. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003551 · Cited by 76
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 82
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers, B., Leaf, D. E., Porta, C., Soler, M. J., & Perazella, M. A. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00630-8 · Cited by 81
Sui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 82
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
β1-Adrenergic Receptor Function, Autoimmunity, and Pathogenesis of Dilated Cardiomyopathy
Jahns, R., Boivin, V., & Lohse, M. J. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.11.002 · Cited by 82
Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma
Koppolu, V., & Vasigala, V. R. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1290_16 · Cited by 79
Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 76
Programmed death-1 checkpoint blockade in acute myeloid leukemia
Sehgal, A. R., Whiteside, T. L., & Boyiadzis, M. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1051028 · Cited by 78
Minnar, C. M., Sckisel, G. D., Proia, D. A., Mirsoian, A., Grossenbacher, S. K., Pai, C.-C. S., Chen, M., Monjazeb, A. M., Kelly, K. L., Blazar, B. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1075114 · Cited by 79
Ni, R., Ihara, K., Miyako, K., Kuromaru, R., Inuo, M., Kohno, H., & Hara, T. (2007) · Human Genetics · doi:10.1007/s00439-006-0309-8 · Cited by 78
Regulatory Role of CD4+T Cells in Myocarditis
Vdovenko, D., & Eriksson, U. (2018) · Journal of Immunology Research · doi:10.1155/2018/4396351 · Cited by 69
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 78
Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications
Lazzerini, P. E., Capecchi, P. L., Guideri, F., Acampa, M., Selvi, E., Bisogno, S., Galeazzi, M., & Pasini, F. L. (2007) · Basic Research in Cardiology · doi:10.1007/s00395-007-0686-8 · Cited by 71
Immune checkpoint inhibitor-related myocarditis
Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 73
Staudt, A., Eichler, P., Trimpert, C., Felix, S. B., & Greinacher, A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.051 · Cited by 73
SEKO, Y., Yagita∥, H., Okumura, K., Azuma, M., & Nagai, R. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.012 · Cited by 72
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 71
Takeuchi, M., Doi, T., Obayashi, K., Hirai, A., Yoneda, K., Tanaka, F., & Iwai, Y. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.007 · Cited by 75
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management
Asnani, A. H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0690-1 · Cited by 71
Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy
Shmilovich, H., Danon, A., Binah, O., Roth, A., Chen, G., Wexler, D., Keren, G., & George, J. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.04.077 · Cited by 66
The Emerging Role of B Lymphocytes in Cardiovascular Disease
Adamo, L., Resende, C. R., & Mann, D. L. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053104 · Cited by 67
Cortellino, S., Quagliariello, V., Delfanti, G., Blaževitš, O., Chiodoni, C., Maurea, N., Mauro, A. D., Tatangelo, F., Pisati, F., Shmahala, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41066-3 · Cited by 73
The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases
Sesărman, A., Vidarsson, G., & Sitaru, C. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0318-6 · Cited by 70
Sun, H., Sun, C., & Xiao, W. (2013) · Cytokine · doi:10.1016/j.cyto.2013.09.016 · Cited by 66
PROTECTING THE PUMP: Controlling Myocardial Inflammatory Responses
Taqueti, V. R., Mitchell, R. N., & Lichtman, A. H. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.040104.124611 · Cited by 68
A Spontaneous Model for Autoimmune Myocarditis Using the Human MHC Molecule HLA-DQ8
Taylor, J. A., Havari, E., McInerney, M. F., Bronson, R., Wucherpfennig, K. W., & Lipes, M. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2651 · Cited by 63
Economopoulou, P., Kotsantis, I., & Psyrri, A. K. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000122 · Cited by 70
Shin, S.-P., Seo, H.-H., Shin, J.-H., Park, H.-B., Lim, D. P., Eom, H., Bae, Y., Kim, I.-H., Choi, K., & Lee, S.-J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.252 · Cited by 67
Immunotherapy opportunities in ovarian cancer
Chu, C., Kim, S. H., June, C. H., & Coukos, G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.243 · Cited by 67
Zhu, R., Sun, H., Yu, K., Zhong, Y., Shi, H., Wei, Y., Su, X., Xu, W., Luo, Q., Zhang, F., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004406 · Cited by 66
Lin, S.-J., Peacock, C. D., Bahl, K., & Welsh, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062150 · Cited by 62
Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.005 · Cited by 61
“Although acute toxicities from anti–PD-1/PD-L1 therapy have been the focus of much research in recent years, the long-term consequences of the immune checkpoint blockade are only beginning to be elucidated, and the incidence of long-term toxicities has not been defined [19-23].”
BackgroundCardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Cozma, A., Sporiș, N.-D., Lazăr, A.-L., Buruiană, A., Ganea, A.-M., Mălinescu, T.-V., Berechet, B. M., Fodor, A., Sitar-Tăut, A., Vlad, C. V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810948 · Cited by 65
Owonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 63
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 65
Cardiotoxicity of Contemporary Anticancer Immunotherapy
Dalbo, N., Patel, R. P., Parikh, R. B., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00867-1 · Cited by 64
Pettersson, K. S. I., Eriksson, S., Wittfooth, S., Engström, E., Nieminen, M. S., & Sinisalo, J. P. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115469 · Cited by 59
Metadata
- Authors
- Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- Mie University (JP)
- Corresponding author
- Honjo, Tasuku
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-11-02
- Volume
- 9
- Issue
- 12
- Pages
- 1477-1483
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2140419562
- Semantic Scholar
- 8b8bf12ad1a303d244e325c58410b356c4ed2945
- Cited by
- 689
- References
- 38
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 44 · 2023: 36 · 2022: 49 · 2021: 49 · 2020: 47 · 2019: 46 · 2018: 28 · 2017: 30 · 2016: 32 · 2015: 19 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- cardiac troponin I, autoantibodies, dilated cardiomyopathy, PD-1 deficiency, autoimmune cardiomyopathy, familial hypertrophic cardiomyopathy, L-type calcium current, cardiac dysfunction, monoclonal antibodies
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Surface, Autoantibodies, Base Sequence, Cardiomyopathy, Dilated, Humans, Mice, Inbred A, Mice, Inbred BALB C, Mice, Nude, Antigens, CD, Rats, Wistar, DNA, Complementary, Mice, Knockout, Troponin I, Calcium Signaling, Myocytes, Cardiac, Apoptosis Regulatory Proteins, Mice, Rats, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.